Please Wait
Applying Filters...
menu
    • menu
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    evonik-m-2025-09-08

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Menu

    0462Z4S4OZ

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 9,745Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Intercept Pulls Liver Disease Drug After Regulator's Request
    Intercept Pulls Liver Disease Drug After Regulator's Request

    12 Sep 2025

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/intercept-pharma-pulls-liver-disease-drug-us-after-regulators-request-2025-09-11/

    REUTERS
    12 Sep 2025
    Share Share
    Intercept Withdraws Ocaliva for PBC from US Market, Trial on Hold
    Intercept Withdraws Ocaliva for PBC from US Market, Trial on Hold

    11 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/11/3148535/23024/en/Intercept-Announces-Voluntary-Withdrawal-of-OCALIVA-for-Primary-Biliary-Cholangitis-PBC-from-the-US-Market-US-Clinical-Trials-Involving-Obeticholic-Acid-Placed-on-Clinical-Hold.html

    GLOBENEWSWIRE
    11 Sep 2025
    Share Share
    EU authorities revoke marketing nod for Advanz Pharma's Ocaliva
    EU authorities revoke marketing nod for Advanz Pharma's Ocaliva

    03 Dec 2024

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/after-temporary-reprieve-intercepts-liver-med-ocaliva-loses-marketing-nod-europe

    FIERCE PHARMA
    03 Dec 2024
    Share Share
    FDA declines full approval for Intercept's liver disease drug
    FDA declines full approval for Intercept's liver disease drug

    13 Nov 2024

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-declines-full-approval-intercepts-liver-disease-drug-2024-11-12/

    REUTERS
    13 Nov 2024
    Share Share
    Intercept Receives CRL from FDA Addressing OCALIVA Snda
    Intercept Receives CRL from FDA Addressing OCALIVA Snda

    12 Nov 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/11/12/2979130/23024/en/Intercept-Receives-Complete-Response-Letter-from-FDA-Addressing-OCALIVA-supplemental-New-Drug-Application-sNDA.html

    GLOBENEWSWIRE
    12 Nov 2024
    Share Share
    Intercept Provides Regulatory Update Regarding sNDA for OCALIVA
    Intercept Provides Regulatory Update Regarding sNDA for OCALIVA

    17 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/17/2964897/23024/en/Intercept-Provides-Regulatory-Update-Regarding-sNDA-for-OCALIVA.html

    GLOBENEWSWIRE
    17 Oct 2024
    Share Share